Who
Jeffrey Robert Ajer
Director
Company insider
Files Form 4 as: Director, Nektar Therapeutics; Director, Viridian Therapeutics; EVP, Chief Commercial Officer, BioMarin Pharmaceutical.
In numbers
- Trades disclosed
- 261
- Buys
- 0
- Sells
- 76
- Bought
- $0
- Sold
- $28.9M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 31 Oct 2012
- Last trade
- 23 Sep 2026
- Last filed
- 25 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Sep 2026filed 25 Sep 2026 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,000 at $0.00 | filing |
| 23 Sep 2026filed 25 Sep 2026 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 23 Sep 2026filed 25 Sep 2026 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 23 Sep 2026filed 25 Sep 2026 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,000 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | VRDN Viridian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,341 at $0.00 | filing |
| 1 Jul 2026filed 2 Jul 2026 | VRDN Viridian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,341 at $0.00 | filing |
| 30 Sep 2025filed 1 Oct 2025 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 1 Jul 2025filed 2 Jul 2025 | VRDN Viridian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —21,000 at $0.00 | filing |
| 7 Apr 2025filed 9 Apr 2025 | VRDN Viridian Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,000 at $0.00 | filing |
| 18 Sep 2024filed 17 Jan 2025 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 2 May 2024filed 6 May 2024 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Sold | $415K5,000 at $82.91 | filing |
| 30 Apr 2024filed 6 May 2024 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | $21K300 at $68.65 | filing |
| 15 Mar 2024filed 19 Mar 2024 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code F | $1.9M22,580 at $83.87 | filing |
| 5 Mar 2024filed 7 Mar 2024 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Sold | $348K4,000 at $87.07 | filing |
| 27 Feb 2024filed 29 Feb 2024 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | —21,440 at $0.00 | filing |
| 27 Feb 2024filed 29 Feb 2024 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | —9,338 at $0.00 | filing |
| 27 Feb 2024filed 29 Feb 2024 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Code A | —6,465 at $0.00 | filing |
| 19 Sep 2023filed 20 Sep 2023 | NKTR Nektar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —85,000 at $0.00 | filing |
| 18 Sep 2023filed 20 Sep 2023 | NKTR Nektar TherapeuticsBiotechnology | SEC FORM 4 Sold | $3,0084,359 at $0.69 | filing |
| 16 Aug 2023filed 17 Aug 2023 | BMRN BioMarin PharmaceuticalBiotechnology | SEC FORM 4 Sold | $450K5,000 at $90.00 | filing |
News
Critical Survey: XTL Biopharmaceuticals (NASDAQ:XTLB) & BioMarin Pharmaceutical (NASDAQ:BMRN)BMRN · tickerreport.com · 18 Oct 2026BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Rating Upgraded by UBS GroupBMRN · tickerreport.com · 17 Oct 2026Nektar Therapeutics (NASDAQ:NKTR) Research Coverage Started at Leerink PartnersNKTR · tickerreport.com · 15 Oct 2026BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price Expected to Rise, Barclays Analyst SaysBMRN · themarketsdaily.com · 14 Oct 2026Nektar Therapeutics (NASDAQ:NKTR) Now Covered by Analysts at Leerink PartnersNKTR · themarketsdaily.com · 13 Oct 2026Nektar Therapeutics (NKTR): $115 Million Lawsuit Victory Over Eli Lilly Clears Multi-Year OverhangNKTR · insidermonkey.com · 7 Oct 2026
0 headlines in the last 90 days name Jeffrey Robert Ajer; 6 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.